TG THERAPEUTICS, INC.TGTXEarnings & Financial Report
TG Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients with B-cell malignancies, autoimmune diseases and neurodegenerative disorders. Its core operating markets are North America and Europe, with key product segments including targeted monoclonal antibodies and oral small molecule treatments.
Revenue
$141.1M
Gross Profit
$122.2M
Operating Profit
$34.8M
Net Profit
$28.2M
Gross Margin
86.6%
Operating Margin
24.7%
Net Margin
20.0%
YoY Growth
92.1%
EPS
$0.17
TG THERAPEUTICS, INC. Q2 FY2025 Financial Summary
TG THERAPEUTICS, INC. reported revenue of $141.1M (up 92.1% YoY) for Q2 FY2025, with a net profit of $28.2M (up 309.8% YoY) (20.0% margin). Cost of goods sold was $18.9M, operating expenses totaled $87.4M.
Key Financial Metrics
| Total Revenue | $141.1M |
|---|---|
| Net Profit | $28.2M |
| Gross Margin | 86.6% |
| Operating Margin | 24.7% |
| Report Period | Q2 FY2025 |
Revenue Breakdown
TG THERAPEUTICS, INC. Q2 FY2025 revenue of $141.1M breaks down across 2 segments, led by Products at $138.8M (98.4% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Products | $138.8M | 98.4% |
| License Revenue | $2.3M | 1.6% |
TG THERAPEUTICS, INC. Revenue by Segment — Quarterly Trend
TG THERAPEUTICS, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Products and License Revenue) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Products | $189.1M | $159.3M | $138.8M | $119.7M |
| License Revenue | — | — | $2.3M | — |
TG THERAPEUTICS, INC. Annual Revenue by Year
TG THERAPEUTICS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $616.3M).
| Year | Annual Revenue |
|---|---|
| 2025 | $616.3M |
| 2024 | $329.0M |
TG THERAPEUTICS, INC. Quarterly Revenue & Net Profit History
TG THERAPEUTICS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $192.6M | +78.0% | $23.0M | 12.0% |
| Q3 FY2025 | $161.7M | +92.8% | $390.9M | 241.7% |
| Q2 FY2025 | $141.1M | +92.1% | $28.2M | 20.0% |
| Q1 FY2025 | $120.9M | +90.4% | $5.1M | 4.2% |
| Q4 FY2024 | $108.2M | +146.0% | $23.3M | 21.6% |
| Q3 FY2024 | $83.9M | -49.4% | $3.9M | 4.6% |
| Q2 FY2024 | $73.5M | +357.0% | $6.9M | 9.4% |
| Q1 FY2024 | $63.5M | +713.5% | $-10.7M | -16.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $63.5M | $73.5M | $83.9M | $108.2M | $120.9M | $141.1M | $161.7M | $192.6M |
| YoY Growth | 713.5% | 357.0% | -49.4% | 146.0% | 90.4% | 92.1% | 92.8% | 78.0% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $373.3M | $401.2M | $586.0M | $577.7M | $656.7M | $702.6M | $1.03B | $1.06B |
| Liabilities | $213.2M | $223.6M | $393.9M | $355.3M | $419.4M | $426.2M | $417.8M | $415.2M |
| Equity | $160.1M | $177.6M | $192.2M | $222.4M | $237.3M | $276.4M | $607.2M | $648.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-8.2M | $5.5M | $-12.2M | $-25.6M | $-28.7M | $7.4M | $-23.2M | $19.7M |